General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-08-02 | 2024-06 | 0.14 | N/A | N/A | N/A |
2024-05-03 | 2024-03 | 0.09 | 0.14 | 0.05 | 55.56% |
2024-03-01 | 2023-12 | 0.07 | 0.12 | 0.05 | 71.43% |
2024-03-01 | 2023-12 | 0.07 | 0.14 | 0.07 | 100.00% |
2023-11-07 | 2023-09 | 0.12 | 0.19 | 0.07 | 58.33% |
2023-11-07 | 2023-09 | 0.12 | 0.17 | 0.05 | 41.67% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-05 | Truist Securities | Upgrade | Buy | Buy |
2023-08-06 | Piper Sandler | Upgrade | Overweight | Overweight |
2023-08-06 | Truist Securities | Upgrade | Buy | Buy |
2023-08-06 | Barclays | Upgrade | Overweight | Overweight |
2023-05-07 | Piper Sandler | Upgrade | Overweight | |
2023-03-28 | Truist Securities | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-05-09 | ALVA EMILY PETERSON | Director | 250.77K | Conversion of Exercise of derivative security |
2024-05-16 | AUTOR DEBORAH M | Director | 93.40K | Sale |
2024-05-09 | BUCHI J. KEVIN | Director | 262.07K | Conversion of Exercise of derivative security |
2024-05-09 | GEORGE JEFFREY P. | Director | 269.54K | Conversion of Exercise of derivative security |
2024-05-09 | KIELY JOHN J. | Director | 255.73K | Conversion of Exercise of derivative security |
2024-03-11 | KONIDARIS TASOS | Chief Financial Officer | 527.32K | Conversion of Exercise of derivative security |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Fosun International Ltd | 21.52M | 66.72M | 13.96% |
2023-06-29 | Vanguard Group Inc | 13.14M | 40.72M | 8.52% |
2023-06-29 | TPG GP A, LLC | 12.33M | 38.22M | 8.00% |
2023-06-29 | Blackrock Inc. | 8.01M | 24.82M | 5.19% |
2023-06-29 | Eversept Partners, LP | 5.27M | 16.32M | 3.41% |
2023-06-29 | Neuberger Berman Group, LLC | 3.75M | 11.62M | 2.43% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 3.99M | 12.37M | 2.59% |
2023-06-29 | Vanguard Small-Cap Index Fund | 3.56M | 11.05M | 2.31% |
2023-08-30 | iShares Russell 2000 ETF | 2.83M | 11.56M | 1.83% |
2023-06-29 | Vanguard Small Cap Value Index Fund | 2.47M | 7.65M | 1.60% |
2023-06-29 | Vanguard Extended Market Index Fund | 1.39M | 4.30M | 0.90% |
2023-08-30 | Neuberger & Berman Intrinsic Value Fd | 1.33M | 5.43M | 0.86% |
No cash, and three billion in debt!!! Kinda wonder when they file bankruptcy
I’ve been following this stock for years, and am surprised they are still in business. Can anyone tell me, how they are still a going concern? They have almost no money, and almost 3 billion in debt. I’m sure there are restrictions on the notes, and at this stock price, some of those notes, could, and probably will be called in. They could be forced to file bankruptcy any day, with these current prices.
Three billion in debt, and only 27 million in cash. You wonder why it’s dropping so fast. They need to raise capital, and that will only dilute this more. No future, pure crap!!!
Debt is still way to high!! Almost 3 billion, with little earnings
Their problem is the nearly 3 billion in debt. It’s going to continue to strangle them. With rates moving up, it’s going to be a bigger problem in the future
Gonna miss, and miss big. Entire industry is in turmoil, and these guys aren’t gonna go against the downward trend. Way too much debt, with lower sales, and lower profit margin. This is a two dollar stock.
People realized that 3 billion in debt, is just too large for them to handle.
Still think that their debt is too much to overcome!!
Still curios how they plan on addressing their debt. Three billion!!! Not sure what their current interest rate is, but they could be paying a couple hundred million a year in interest.
Garbage company, way too much debt, with no way of paying it off. Much better generic companies. Check out LCI, great future, and debt under control.
Three billion in debt, and no plan on how to reduce it. One hiccup, and lights out
Much better generic drug play is LCI. They’re doing everything right. All debt refinanced and no longer an issue. Advair launch next year, should add at least 500 million in sales. The following year should see the launch of generic insulin, with possible sales of 1 billion. Following year should be the launch of another insulin product and another bronchial product with an additional billion in sales. Five year plan, no debt, and over 2.5 billion in sales. AMRX is dead in the water, with no plan to service their multi billion in debt.
These guys need to stop spending, and start dealing with their debt. Over 3 billion in debt, and they keep spending. They are digging their hole to deep, to ever be able to get out.
I’m out!!! This stock just can’t make anything happen. Three billion in debt, and they keep spending, they need to pay this down. They completely screwed up the Jerome Stevens ( Levothyroxine) deal. They probably paid well over 200 million for a crap item. They should have let Lannett keep the item. Looks like Lannett was the smart one there. These guys can’t do anything right!! Good luck
The problem with this company, is they keep spending money they don’t have. Three billion in debt, and they’re buying companies. They need to concentrate on reducing debt. This is a bankruptcy waiting to happen!!
Even if sales pick way up, it’s not a high profit item, and they obviously can’t raise the price, as well as mylan & teva giving it to the government. Don’t see a huge play here, especially remdesivir is actually showing some really positive results. This could be a good company to invest in , but I’d be careful. ——————————————————-
Africa is just behind other countries, it’s starting now, and will probably be one of the hardest hit, since they lack in hospitals and medical equipment!! I hope it’s any one of these drug companies that get it. We need something, and we need it fast, but I’m not hanging my hat on trump getting behind this drug. He may know something, but the fda isn’t agreeing with him on this one. Let’s wait, see and hope!! There’s a few hats in the ring. Three or four drugs that they are working on, just hope it’s one of them!!!————
I’ve heard of so many side effects from this combination. It’s so confusing, Trump is all over this drug, when the UK won’t let the brand Kaletra be exported any longer because it’s showing so much promise. The Israeli government is breaking the patent on Kaletra because it shows so much promise, and the USA is get behind this malaria drug from 1944 with tons of horrible side effects. LCI is the only maker of the generic Kaletra, if it’s the drug that cured this mess, that company is gonna run. This drug has several competitors, and Mylan & Teva are giving it to the government. ——-/////——/////———————/